MAPT and Alzheimer disease: In practice, a high CTRED label with amyloid and tau as primary indicators facilitates discussions about anti-amyloid monoclonal antibodies (such as lecanemab and donanemab) in accordance with the Appropriate Use Recommendations for early AD, which include biomarker confirmation and ARIA risk management [54,55].